visualvisitorlogo
  • Our Platform downarrow
    Powerful Sales
    Intelligence     dashboard
    Platform Overview
    Buyer Intent Data
    B2B Prospect Data     Website Visitor ID Email Tracking
  • Why?downarrow
    Your Challenges Our Data See For Yourself
  • Pricing
  • Resourcesdownarrow
    Resellers
    Add Onsdrop
    Call Tracking     Keyword Level Tracking Reputation Management
    Integrations About Us
    Contactdrop
    Atlanta Jacksonville
    Blog Careers Support
    • Login Free Trial Schedule A Demo
    × Our Platform downarrow
    Why? downarrow
    Pricing Resources downarrow
    visualvisitorlogo ☰

    Alexion Pharmaceuticals, Inc.

    Get Full Access

    Description

    • Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway ALXN1850, an enzyme replacement therapy ALXN2060 for treating transthyretin amyloidosis and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
    • location

      Headquarters:121 Seaport Blvd , Boston, Massachusetts, United States

      More
    • Alexion Pharmaceuticals, Inc. phone

      Phone Number: +1 475-230-2596

    • Alexion Pharmaceuticals, Inc. website

      Website: https://www.alexion.com

    • Alexion Pharmaceuticals, Inc. employees

      Employees:3671

    • Alexion Pharmaceuticals, Inc. revenue

      Revenue:> $1B

    • Alexion Pharmaceuticals, Inc. legal name

      Legal Name:Alexion Pharmaceuticals, Inc.

    • Alexion Pharmaceuticals, Inc.'s Social Media

      Alexion Pharmaceuticals, Inc. linkedin Alexion Pharmaceuticals, Inc. twitter
    • done Is this data correct?

    • |  NAICS Code: 541713  |

        NYSE: ALXN

      Show More
    Person level website identification

    Director, External Commercial Chief Marketing Officer Qa for Alexion Pharmaceuticals, Inc.

    Leona Cantwell

    Director, External Commercial Chief Marketing Officer Qa

    Person level website visitor identification

    Sell more in less time!

    Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

    View Employees

    Leona Cantwell

    Director, External Commercial Chief Marketing Officer Qa

    Declan Dunne

    Senior Director Global Chief Marketing Officer Business Management

    George Llado

    Senior Vice President And Chief Information Officer

    Ulrich Goldmann

    Chief Medical Officer, Senior Vice President Global Head Medical Affairs

    Jake Guterman

    Chief Of Staff To The Head Of Medical And Chief Marketing Officer

    Frequently Asked Questions regarding Alexion Pharmaceuticals, Inc.

    • Where are Alexion Pharmaceuticals, Inc.'s Headquarters?

      Alexion Pharmaceuticals, Inc.'s Headquarters are in 121 Seaport Blvd ,Boston,Massachusetts,United States

    • What is Alexion Pharmaceuticals, Inc.'s phone number?

      Alexion Pharmaceuticals, Inc.'s phone number is +1 475-230-2596

    • What is Alexion Pharmaceuticals, Inc.'s stock symbol?

      Alexion Pharmaceuticals, Inc.'s stock symbol is ALXN

    • What is Alexion Pharmaceuticals, Inc.'s official website?

      Alexion Pharmaceuticals, Inc.'s official website is https://www.alexion.com

    • What is Alexion Pharmaceuticals, Inc.'s Revenue?

      Alexion Pharmaceuticals, Inc.'s revenue is > $1B

    • What is Alexion Pharmaceuticals, Inc.'s NAICS code?

      Alexion Pharmaceuticals, Inc.'s NAICS code is 541713

    • How many employees are working in Alexion Pharmaceuticals, Inc.

      Alexion Pharmaceuticals, Inc. has 3671 employees

    • What is Alexion Pharmaceuticals, Inc.'s Industry?

      Alexion Pharmaceuticals, Inc. is in the industry of Biotechnology

    Company Directory